Table 4: Incidence and prevalence of acute clinician reported toxicity in RCTs (emboldened text indicates studies where a significant difference in primary outcome was demonstrated).

Type of Toxicity & how reported		% of toxicity		Treatment type	
ACUTE EFFECTS-clinician reported					
Genitourinary symptoms					
Detail not specified					
Grade 1	RTOG	**37%(70.2Gy); 29% (79.2Gy)**	[72]	Conventional 3D conformal RT	
Grade 2		**54%(70.2Gy); 60% (79.2Gy)**			
≥ Grade 2		40%	[49]	Conventional 3D conformal RT & 9mth prior TAD	
		47%		Hypofractionated 3D conformal RT & 9 mth prior TAD	
	CTCAE V 2.0 & RTOG	15.1	[64]	Conventional 3D conformal RT	
		9.7%		CIMRT	
Grade 3	RTOG	**0%(70.2Gy); 1% (79.2Gy)**	[72]	Conventional 3D conformal RT	
		2%	[63]		
		2%		Conventional 3D conformal RT with HT	
Bladder					
≤ Grade 2 Recorded at 18 weeks	RTOG	**7.0% (74Gy)**	[58]	CIMRT	3-6 mth AS before and during RT
		7.6% (60Gy)		HIMRT	
		7.0% (57Gy)			
Retention					
Catheterised		7.9% (day 0 MXM)) 6.2% (7 days prior MXM)	[55]	EBRT with BT & meloxicam	
Prostate Oedema					
Calculated as a ratio of MRI-determined prostate volume at 1 month to baseline determined prostate volume		1.01% (day 0 MXM 1.05% (MXM)7 days before)	[55]	EBRT with BT & meloxicam	
Dysurea					
Measured as change from baseline at 1mth and 3mth	IPSS	**1 mth:** 8.4% day 0 (MXM); 8.8% (MXM 7 days before) **3mth** 7.9% (day 0 MXM) 6.2% (MXM 7 days before)	[55]	EBRT with BT & meloxicam	

Type of Toxicity & how reported		% of toxicity		Treatment type	
Gastrointestinal symptoms					
Detail not specified					
Grade 1	RTOG	**39%(70.2Gy); 26% (79.2Gy)**	[72]	Conventional 3D conformal RT	
Grade 2		**44%(70.2Gy); 60% (79.2Gy)**			
		21%	[49]		
		35%		Hypofractionated 3D conformal RT	
	CTCAE V 2.0 RTOG	15.1%	[64]	Conventional 3D conformal RT	
		9.7%		CIMRT	
	NCI-CTC V3.0 RTOG	**10%**	[60]	3D Conformal RT with HT & EMP	
≤ Grade 2 Recorded at 18 weeks	RTOG	**2.3% (74Gy)**	[58]	CIMRT	Short-course androgen suppression for 3–6 months before & during RT
		2.3% (57Gy); 0.8% (60Gy)		HIMRT	
Grade 3	RTOG	**1% ≥3 J**	[63]	Conventional 3D conformal RT	
		1% ≥3 J		Conventional 3D conformal RT with HT	
		3%(70.2Gy); 2% (79.2Gy)	[72]	Conventional 3D conformal RT	
Hepatic toxicity					
Grade 1	**RTOG**	**1%**	[63]	Conventional 3D conformal RT	
		20%		Conventional 3D conformal RT with HT	
Grade 2		**5%**			
Grade 3		**5%**			
Grade 4		**1 %**			

Key: 3D-Three dimensional; EMP-estramustine phosphate;BT- Brachytherapy; HT-Hormone therapy ; CIMRT- Conventional intensity modulated radiotherapy; HIMRT- Hypofractionated intensity modulated radiotherapy; MXM-Meloxicam; TAD-Total androgen deprivation; TRUS (transrectal ultrasound); AS-Androgen Supression; Mth=Month; Yr =year; NCI-CTC-National Cancer Institute Common Toxicity Criteria; Radiation Therapy Oncology group –RTOG; IPSS-International prostate symptom score; MRI-magnetic resonance imaging; ⩾ greater than and equal to; ⩽- less than or equal to; Mth-Month; Yr-Year**. NB table only includes papers reporting figures for incidence, prevalence and proportion of toxicity**.

Table 5: Incidence and prevalence of late clinician reported toxicity in RCTs (emboldened text indicates studies where a significant difference in primary outcome was demonstrated).

Type of Toxicity, how &when reported		% of toxicity		Treatment type
LATE EFFECTS-clinician reported				
Genitourinary symptoms				
Not specified				
Grade 1	10yrs	**42%(70.2Gy) ; 45% (79.2Gy)**	[72]	Conventional 3D conformal RT
		22%(70.2Gy) ; 27 %(79.2Gy)		
Grade 1-2	3 yrs NCI-CTC v3.0	**42%**	[69]	HT
		43%		Conventional 3D conformal RT with HT
Grade 2	7yrs	16 % (4mth HT) 17 % (8mth HT)	[56]	Conventional 3D conformal RT with HT
≥ Grade 2	3yrs LENT-SOMA	11 %	[49]	Conventional 3D conformal RT
		16 %		Hypofractionated 3D conformal RT
	5 yrs prevalence RTOG	14.6%	[67]	CIMRT
		15.3%		HIMRT
	7yrs Cumulative Incidence RTOG	16% (4mth HT) (7yrs)	[56]	Conventional 3D conformal RT with HT
		17% (8mth HT)(7yrs)		
Grade 3	10 yrs	**2%(70.2Gy); 2% (79.2Gy)**	[72]	Conventional 3D conformal RT
	3 yrs NCI-CTC v3.0	**2%**	[69]	HT
		2%		Conventional 3D conformal RT with HT
≥Grade 3	2yrs	**6 %**	[63]	Conventional 3D conformal RT
	5yrs	**9 %**	[62]	
	7yrs	**4 %**		
	2yrs	**8 %**	[63]	Conventional 3D conformal RT with HT
	5yrs	**0 %**	[62]	
	7yrs	**2 %**		
Urinary toxicity				
Grade 1	Cumulative rate at 5 years RTOG	**18.9 % (70Gy); 20.9% (80Gy)**	[53]	Conventional 3D conformal RT
		22 % (70Gy); 25% (80Gy)		
Grade 2		**7.1 % (70Gy); 15.6% (80Gy)**		

	LENT-SOMA	**13.7 %(70Gy); 20.9% (80Gy)**			
	2yrs	**74 %**		[60]	Conventional 3D conformal RT with HT
		90 %			Conventional 3D Conformal RT with HT & EMP
≥Grade 2	5yrs RTOG	**10 % (70Gy); 17.5% (80Gy)**		[53]	Conventional 3D conformal RT
	5 yrs RTOG	14.6%		[67]	CIMRT
		15.3			HIMRT
Grade 3	2yrs	**26%**		[60]	3D conformal RT with HT
		10%			3D Conformal RT with HT & EMP
*1 patient had grade 4 toxicity (RTOG)	Cumulative rate at 5 years RTOG LENT-SOMA	**2.6% (70Gy); 1.9% (80Gy)*** **3.2% (70Gy); 5.4% (80Gy)**		[53]	Conventional 3D conformal RT
Grade 4	LENT-SOMA	**0.4% (70Gy); 0.6% (80Gy)**			
Decreased stream					
Grade1	LENT-SOMA% change in score from baseline (93) to 5yrs	**5%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade 2		**1%**			
Incontinence					
Grade 1	LENT-SOMA% change in score from baseline (93) to 5yrs	**6%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade2		**1%**			
Urinary frequency					
Grade 1	LENT-SOMA% change in score from baseline (85) to 5yrs	**10%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade2		**4%**			
Nocturnal frequency					
Grade 1	MH change in score from baseline (88) to 5yrs	**12%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade2		**2%**			
Grade 3		**1%**			
Cystitis					
≥ Grade 2	5 yrs RTOG	**15% (70Gy); 19% (80Gy)**		[53]	Conventional 3D conformal RT
Haematurea					
Grade 1	LENT-SOMA% change in score from baseline to 5yrs	**2%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
≥ Grade 2	5 yrs RTOG	**10% (70Gy); 14% (80Gy)**		[53]	Conventional 3D conformal RT
Urinary obstruction					
≥ Grade 2	5 yrs RTOG	**6% (70Gy); 9% (80Gy)**		[53]	Conventional 3D conformal RT

Bladder					
Grade 1	Prevalence at 2 yrs RMH LENT-SOMA	**43.9 (74Gy)** **20.4 (74Gy)**	[58]	CIMRT	3-6 mth AS before and during RT
		28.3% (60Gy) ; 35.0%(57Gy) **18.2% (60Gy) ; 19.7%(57Gy)**		HIMRT	
≥Grade 2		**10.8%(74Gy) 15.3% (74Gy)**		CIMRT	
		6.5% (60Gy); 6.3% (57Gy) **12.3% (60Gy);12.0% (57Gy)**		HIMRT	
Grade 3		**4.4%(74Gy)**		CIMRT	
		5.8% (60Gy);3.5% (57Gy)		HIMRT	
Gastrointestinal symptoms					
Not specified					
Grade 1	2 yr prevalence RMH LENT-SOMA	**28.9% (74Gy)**	[58]	CIMRT	3-6 mth AS before and during RT
		22.% (74Gy)			
		18.1% (60Gy); 20.3% (57Gy)		HIMRT	
		16.8% (60)Gy; 15.5% (57Gy)			
	10 yrs	**35%(70.2Gy); 41% (79.2Gy)**	[72]	Conventional 3D conformal RT	
Grade 2		**13%(70.2Gy); 24% (79.2Gy)**		Conventional 3D conformal RT	
	1yr RTOG	12%(4 mth HT) 12% (8 mth HT)	[56]	Conventional 3D conformal RT	
	3yrs	22%	[64]	Conventional 3D conformal RT	
		15.1%		CIMRT	3-6 mth AS before and during RT
≥Grade 2	2 yr prevalence RMH LENT-SOMA	**5.8% (74Gy)** **9.4% (74Gy)**	[58]	CIMRT	
		2.9% (60gy); 0.7% ≥2 (57Gy) **5.1% (60gy); 4.2% ≥2 (57Gy)**		HIMRT	
	7yrs Cumulative Incidence RTOG	12% (4mth HT)	[56]	Conventional 3D conformal RT with HT	
		17% (8mth HT)			
Grade 3	2 yrs RTOG	**3%**	[63]	Conventional 3D conformal RT	
		3%		Conventional 3D conformal RT with HT	
	2 yr prevalence RMH LENT-SOMA	**1.4% (74Gy)**	[58]	CIMRT	3-6 mth AS before and during RT
		0.7%(60Gy); 0.7%(57Gy)		HIMRT	
≥Grade 3	5 yrs* 7yrs Dische scales	**9% ***	[62]	Conventional 3D conformal RT	
		4%			
		0% *		Conventional 3D conformal RT with HT	
		2%			

Rectal toxicity				
Grade 1	Cumulative rate at 5 years RTOG LENT-SOMA	**19% (70Gy); 22% (80Gy)**	[53]	Conventional 3D conformal RT
Grade 2		**18.3% (70Gy); 15% (80Gy)**		
		12.4% (70Gy); 13.7% (80Gy)		
		18.3% (70Gy); 20.2% (80Gy)		
≥ Grade 2	3yrs LENT-SOMA	**11%**	[49]	Conventional 3D conformal RT
		14%		Conventional 3D conformal RT with HT
	5yrs RTOG	**14% (70Gy); 19.5% (80Gy)**	[53]	Conventional 3D conformal RT
Grade 3	Cumulative rate at 5 years RTOG LENT-SOMA	**1.9% (70Gy); 5.9% (80Gy)**		
		1.9% (70Gy); 6.5% (80Gy)		
Diarrhoea/stool frequency				
Grade 1	LENT-SOMA% Change form Baseline (89) at 5 yrs	**10%** **64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade 1	Cumulative incidence RTOG, LENT-SOMA 5 yrs	**33% (64Gy); 34%(74Gy)** **44% (64Gy); 46%(74Gy)**	[68]	Conventional 3D conformal RT with HT
Grade 1-2	3 yrs NCI-CTC v 3.0	**8%**	[69]	HT
		13%		Conventional 3D conformal RT with HT
Grade 2	LENT-SOMA% Change form Baseline (89) at 5 yrs	**2%** **64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade 2	5 yrs Cumulative incidence RTOG RMH LENT-SOMA	**10% (64Gy); 15%(74Gy)** **6% (64Gy); 12%(74Gy)**	[68]	Conventional 3D conformal RT with HT
Grade 3		**1% (64Gy); 4%(74Gy)** **0% (64Gy); 2%(74Gy)**		
≥Grade 3	3 yrs NCI-CTC v3.0	**< 1%**	[69]	Conventional 3D conformal RT
		1%		Conventional 3D conformal RT with HT
Bowel frequency				
Mild	5 yrs Cumulative incidence RMH LENT-SOMA	**9% (64Gy); 14%(74Gy)**	[68]	Conventional 3D conformal RT with HT
Moderate		**2% (64Gy); 6%(74Gy)**		
Stool frequency				
≥ Grade 1		**44% (64Gy); 46% (74Gy)**		
≥ Grade 2		**6% (64Gy); 12% (74Gy)**		

≥ Grade 3		**0% (64Gy); 2% (74Gy)**			
Rectal bleeding					
Mild		**43 % (64gy); 53 %(74Gy)**			
Moderate		**11% (64Gy);21% (74Gy)**			
Severe		**1% (64Gy);1% (74Gy)**			
≥ Grade 2		**22% (64Gy); 32%(74Gy)**			
≥ Grade 3		**3% (64Gy); 10%(74Gy)**			
≥ Grade 4		**1% (64Gy); 1%(74Gy)**			
Grade 1	RTOG % Change form Baseline (82) at 5 yrs	**16%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade 1-2	3 yrs NCI-CTC v3.0	**5%**		[69]	HT
		12%			Conventional 3D conformal RT with HT
Grade 2	RTOG % Change form Baseline (82) at 5 yrs	**3%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
≥Grade 2	5yrs RTOG	**19% (70Gy)**		[53]	Conventional 3D conformal RT
		28% (80Gy)			
Grade 3	3 yrs NCI-CTC v 3.0	**1%**		[69]	Conventional 3D conformal RT
		< 1%			Conventional 3D conformal RT with HT
≥Grade 3	5 yrs Cumulative incidence LENT-SOMA	**3% (64Gy); 10%(74Gy)**		[68]	Conventional 3D conformal RT with HT
≥Grade 4		**1% (64Gy); 1%(74Gy)**			
Sphincter control					
Grade 1	LENT-SOMA% Change form Baseline (95) at 5 yrs	**2%**	**64 & 74Gy**	[51]	Conventional 3D conformal RT with HT
Grade 2		**1%**			
Proctitis					
Grade 1	5yrs cumulative incidence RTOG	**42% (64Gy);50 %(74Gy)**		[68]	Conventional 3D conformal RT with HT
Grade 2		**15 % (64Gy);25% (74Gy)**			
		7% (70Gy); 8% (80Gys)			
Grade 3		**4% (64Gy);7%(74Gy)**			
Rectal pain					
Grade 2	5yrs cumulative incidence RTOG	**5% (64Gy);8%(74Gy)**		[68]	Conventional 3D conformal RT with HT
Grade 3		**0% (64Gy);2%(74Gy)**			
Anorexia					

Grade 1	2 years	**11%**	[60]	Conventional 3D conformal RT with HT	
		25%		3D Conformal RT with HT & EMP	
Grade 2		**5%**			
Nausea					
Grade 1	2 years	**15%**	[60]	Conventional 3D Conformal RT with HT & EMP	
Grade 2		**5%**			
Erectile dysfunction					
Grade 1	2 yr prevalence LENT-SOMA	**74Gy 95.0%**	[58]	CIMRT	3-6 mth AS before and during RT
		60Gy 94% ; 57Gy 90.5%		HIMRT	
	7 yrs	18%(4mth); 21%(8mth)	[57]	3D Conformal RT with HT	
Grade 2	2 yr prevalence LENT-SOMA	**91% (74Gy)**	[58]	CIMRT	3-6 mth AS before and during RT
		90.9% (60 Gy); 89.3% (57Gy)		HIMRT	
	7 yrs	5%(4mth); 3%(8mth)	[57]	3D Conformal RT with HT	
Grade 3	2 yr prevalence LENT-SOMA	**80% (74Gy**	[57]	CIMRT	3-6 mth AS before and during RT
		79.8% (60Gy) ; 81.8% (57Gy)		HIMRT	
	7 yrs	10%(4mth) ; 17%(8mth)	[57]	3D Conformal RT with HT	
Grade 4	2 yr prevalence LENT-SOMA	**64.6% (74Gy)**	[58]	CIMRT	3-6 mth AS before and during RT
		70.1 (60Gy); 64.6 (57Gy)		HIMRT	
	7 yrs	47%(4mth); 42%(8mth)	[57]	3D Conformal RT with HT	
Cardiac effects					
Grade 1	2 yrs	**1%**	[63]	Conventional 3D conformal RT	
Gynaecomastia					
Grade 1	2yrs NCI-CTC V 3.0 RTOG	**45%**	[60]	3D Conformal RT with HT & EMP	
Anaemia					
Grade 1		**65%**		3D Conformal RT with HT & EMP	
		74%		3D Conformal RT with HT	
Grade 2		**10%**		3D Conformal RT with HT & EMP	
		26%		3D Conformal RT with HT	

Key: Three dimensional-3D; EMP-estramustine phosphate;BT- Brachytherapy; HT-Hormone therapy ; CIMRT- Conventional intensity modulated radiotherapy;HIMRT-Hypofractionated intensity modulated radiotherapy; TAD-Total androgen deprivation; AS-Androgen suppression; NCI-CTC- Canadian National Cancer Institute Common Toxicity Criteria; RTOG- Radiation Therapy Oncology Group; LENT-SOMA -Late Effect in Normal Tissue-Subjective Objective Management Analytic – Scales; RMH-Royal Marsden Hospital Scale; Mth=Month; Yr =year, ≥ greater than and equal to; ≤- less than or equal to**. NB table only includes papers reporting figures of incidence, prevalence and proportion of toxicity.**

Table 6: Incidence of late patient reported toxicity and Quality of life (QOL) scores in RCTs (emboldened text indicates studies where a significant difference in primary outcome was demonstrated).

Type of Toxicity or QOL how & when reported		% of toxicity or QOL score					Treatment type
LATE EFFECTS-patient reported							
Genitourinary symptoms							
Mean score change form baseline ↑ score =↑ QOL * 6mth 3yrs	FACT-P	**-6.1*** **-5.2**				[69]	HT
		0.1 * **-5.5**					Conventional 3D conformal RT with HT
		-1.4* **-0.6**					HT
		0.1* **-0.4**					Conventional 3D conformal RT with HT
Increase from 13 at baseline	QLQC-30 PR25	**Mean score 17**	**70 & 80Gy**			[53]	Conventional 3D conformal RT
Gastrointestinal symptoms							
Bowel problems							
Composite bowel score: 0 (min dysfunction) to 100 (max dysfunction)	7 yr MGH	**7.3 (70.2 Gy); 9.1 (79.2)**				[65]	Conventional 3D conformal RT
Mean score change form baseline * 6mth 3yrs	EORTC	**-1.3*** **-0.3**				[69]	HT
		3.4* **1.7**					Conventional 3D conformal RT & HT
Faecal/rectal urgency							
Grade 1	UCLA-PCI % change in score from baseline (84) to 5yrs	**7%**	**64 & 74Gy**			[51] *	Conventional 3D conformal RT with HT
Grade 2		**5 %**					
Grade 3		**3%**					
Grade 4		**2%**					
Mild	UCLA-PCI Cumulative incidence at 5yrs	**57%**	64Gy	**61%**	74Gy	[68]	Conventional 3D conformal RT with HT
Moderate		**32%**		**34%**			
Severe		**11%**		**19%**			
Bowel distress							
Mild	UCLA-PCI Cumulative incidence at 5yrs	**68%**	64Gy	**61%**	74Gy	[68]	Conventional 3D conformal RT with HT
Moderate		**29%**		**32%**			
Severe		**4%**		**5%**			

Bowel problems							
Mild	UCLA-PCI Cumulative incidence at 5yrs	**46%**	**64Gy**	**46%**	74Gy	[68]	Conventional 3D conformal RT with HT
Moderate		**26%**		**29%**			
Severe		**6%**		**8%**			
Trouble moving bowels							
Mild	FACT-P Cumulative incidence at 5yrs	**57%**	**64Gy**	**56%**	**74Gy**	[68]	Conventional 3D conformal RT with HT
Moderate		**12%**		**17%**			
Severe		**5%**		**9%**			
Loose stools							
Grade 1	UCLA-PCI % change in score from baseline (70) to 5 yrs	**24%**	**64 & 74Gy**			[51]	Conventional 3D conformal RT
Grade 2		**6 %**					
Grade 3		**1%**					
Bowel disorders							
Point increase from baseline	QLQC-30 PR25	**Mean score 8**	**70 & 80Gy**			[53]	Conventional 3D conformal RT
Treatment related symptoms							
Increase from 5 at baseline	QLQC-30 PR25	**8 score**	**70 & 80Gy**			[53]	Conventional 3D conformal RT
Quality of life							
Global QOl score							
Mean score change form baseline ↑ score = ↑ symptoms * 6mth 3yrs	FACT-P	**4.3***				[69]	HT
		2.5					Conventional 3D conformal RT with HT
		-3.0*					
		-1.1					
	EORTC-PR13	**-1.74***					HT
		-9.4					
		8.98*					Conventional 3D conformal RT with HT
		-11.4					
QOL subscales							
Physical Health Summary	SF-36 (summary scores) *6 mths 3 yrs	68Gy	78Gy			[46]	Conventional 3D conformal RT
		75.4*	75.5*				
Mental health Summary		73.2	71.8				
		78.1*	77.6*				
Physical functioning		76.7	76.1				
		79.0*	76.0*				
Role -physical		81.1	75.0				
		68.4*	71.9*				
General health		69.1	66.4				
		67.2*	61.1*				

		65.2	62.4		
Vitality		68.2*	67.5*		
		68.2	64.7		
Social functioning		68.5*	85.3*		
		84.0	83.0		
Role-emotional		80.3*	79.8*		
		80.0	80.1		
Mental health		79.0*	75.9*		
		79.0	76.9		
Physical function					
Mean score change from baseline ↑ score = ↑ symptoms * 6mth 3yrs	FACT-P	**-4.1* -6.1**		[69]	HT
		-7.6*- -5.5			Conventional 3D conformal RT with HT
	EORTC-PR13	**-3.5* -9.2**			HT
		-3.8 -10.2			Conventional 3D conformal RT with HT
Mean score *Grade 2≥ GU toxicity No toxicity	FACT G 10yrs	**91.0**		[62]	EBRT & EBRT with HTR Brachytherapy Conventional 3D conformal RT
		85.5*			
	FACT-P 1yr	**127.4**			
		116.4*			
	FACT-P TOI	**85.4**			
		76.3*			
Mean score *Grade 3≥ GU toxicity No toxicity	FACT- G	**89.7**			
		81.7*			
	FACT -P	**124.6**			
		110.1*			
	FACT-P TOI	**83.1**			
		71.0*			
Erectile dysfunction					
Always/almost always able to have an erection	SAQ	**21%**		[63]	Conventional 3D conformal RT
		31%			Conventional 3D conformal RT & HT
Sexual functioning point decrease from baseline 5yrs	QLQC-30 PR25	**↓19 points 70Gy & 80Gy**		[53]	Conventional 3D conformal RT
Patients reporting a degree of sexual functioning 5yrs		**38 70Gy & 80Gy**			

Key: 3D-Three dimensional; EMP-estramustine phosphate;BT- Brachytherapy; HT-Hormone therapy ; CIMRT- Conventional intensity modulated radiotherapy; HIMRT-Hypofractionated intensity modulated radiotherapy; MXM-Meloxicam; TAD-Total androgen deprivation; AS-Androgen suppression; UCLA-PCI-University of California, Los Angeles, Prostate Cancer Index; EORTC QLQ-C30-European Organisation for Research and Treatment of Cancer-30 (30 questions) -PR13-prostate-specific module (13 quesitons); FACT-G –Functional Assessment of Cancer Therapy (General); FACT-P- Functional Assessment of Cancer Therapy (Prostate); TOI-Trial Outcome Index; SAQ- Sexual adjustment questionnaire; SF-36- Short Form (36) Health Survey (SF-36); MGH- Massachusetts General Hospital –MGH; Mth=Month; Yr =year; ≥ greater than and equal to; ≤- less than or equal to. **NB table only includes papers reporting figures for incidence, prevalence and proportion of toxicity & mean PRO scores.**